VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF) today
announced that it will begin an observational study on the use of cannabinoids
as therapy for chronic pain. A group of well-known pain specialists will lead
the study, taking place in Melbourne, Australia, which expects to provide
long-term (24 month) data in order to evaluate the efficacy of medical cannabis
in treating pain and further support development of VIVO’s portfolio of medical
cannabis products. VIVO is funding the effort in the form of a research grant
to its partner in the study, Australian Medical Cannabis Service (“AMCS”).
“Driven by unmet clinical needs, medical cannabis products and treatment plans
continue to gain momentum in Australia,” VIVO Chief Executive Officer Barry
Fishman said in the news release. “The Study will help to inform VIVO’s product
development through data gathered from both patients and physicians. This
access to primary data is expected to continue to ensure our products address
the specific health and wellness needs of our clients and customers, something
that we believe provides distinct advantage. We remain committed to ensuring
Australians have access to our medical cannabis, and to our efforts to change
the way people view cannabis.”
To view the full press release, visit http://ibn.fm/uuPMu
About VIVO Cannabis(TM)
VIVO Cannabis(TM), based in Napanee, Ontario, is recognized
for trusted, high-quality products and services. It holds production and sales
licenses from Health Canada and operates world-class indoor cultivation
facilities with proprietary plant-growing technology. VIVO has a collection of
premium brands targeting unique customer segments, including Beacon
Medical(TM), FIRESIDE(TM), Canna Farms(TM) and Lumina(TM). In August 2018, VIVO
acquired Canna Farms, a premium cannabis company based in Hope, British
Columbia. Canna Farms was B.C.’s first Licensed Producer and has several years
of craft cultivation experience and expertise, as well as a significant patient
base and positive cash flow. The Company is significantly expanding its
production capacity and pursuing partnership and product development
opportunities domestically, as well as in select international markets,
including Germany and Australia. VIVO also operates Harvest Medicine, a
patient-centric and highly scalable network of specialty medical cannabis
clinics as well as a free telemedicine app. VIVO has a healthy balance sheet
and is well-positioned to accelerate its growth in Canada and internationally.
For more information, visit the company’s website at www.VivoCannabis.com.
NOTE TO INVESTORS: The latest news and updates
relating to VVCIF are available in the company’s newsroom at http://ibn.fm/VVCIF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
